Zai Lab Ltd

On November 20, 2024, Dr. Samantha (Ying) Du, the Company’s Founder, Chief Executive officer, and Chairperson of the Board, adopted a new written Rule 10b5-1 trading arrangement, for (1) the acquisition and sale of up to 589,165 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2025 and (2) for the acquisition of up to 604,376 ADSs upon the exercise of previously awarded options that are scheduled to expire in 2025. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 20, 2025.

On November 20, 2024, William Lis, one of the Company’sdirectors, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 26,690 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than June 1, 2026.

On November 22, 2024, Rafael Amado, the Company’s President and Head of Global Research and Development, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 9,000 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 17, 2025.

On November 22, 2024, F. Ty Edmondson, the Company’s Chief Legal Officer, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 28,872 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 21, 2025.

Other than as described above, during the fourth quarter of 2024, none of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) hasadopted orterminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K).

-89-